The World Health Organization (WHO) Global TB Program launched a call for case studies and best practices on adaptation and implementation of WHO’s Multisectoral Accountability Framework to end TB (MAF-TB). Political leaders, country officials within and beyond the health sector, program managers, civil society and affected communities, the private sector, UN agencies, partners, funders, and other governmental and non-governmental TB stakeholders are invited to submit examples of relevant case studies.

In a recent study published in the journal BMC Public Health, a team of researchers from Malaysia described a mobile phone application called Gamified-Real-Time Video Observed Therapy or GRVOTS designed to motivate tuberculosis patients to adhere to their treatment regimen through improved patient tracking and enhanced engagement with their doctors through the mobile application.

Key takeaways:

Virologic suppression can be maintained among patients with HIV infection receiving integrase strand transfer inhibitor (INSTI)-containing antiretroviral therapy (ART) in combination with short-course rifapentine-based regimens for latent tuberculosis (TB) management, according to study results published in Clinical Infectious Diseases.

NAIROBI, Jan. 22 -- Kenya's Ministry of Health on Monday launched the national strategic plan, with the aim of eliminating tuberculosis (TB), leprosy and other lung complications by 2030.

A novel approach to studying the progression of tuberculosis (TB) from infection to disease has identified and treated people at increased risk of developing the disease that current methods of testing would not.

• ProteinLogic, Cambridge, UK and Stellenbosch University, South Africa collaboration study funded by Bill & Melinda Gates Foundation.
• ProteinLogic extends ImmiPrint® Technology to address TB antimicrobial chemotherapy response monitoring.
• ProteinLogic ImmiPrint® diagnostic pattern of soluble immune proteins in blood and other body fluids portfolio defined using machine learning.
• ImmiPrint® off-the-shelf diagnostics and disease progression monitoring tests address multiple disease areas including infectious diseases and oncology.
• ImmiPrint® technology applicable to resource-rich and emerging economy clinical settings.

CAMBRIDGE, UK (2024-01-22): ProteinLogic, a biomarker discovery and commercialization company and Stellenbosch University, today announced that they have received a $1.35 million grant from the Bill & Melinda Gates Foundation to accelerate the development of ImmiPrint® Technology to monitor treatment responses to TB antimicrobial chemotherapy. The collaborative project was conceived and developed with the assistance of PTNG Consulting, a specialised science consultancy. PTNG Consulting will oversee the project management of this undertaking.

RESIST-TB will host its first TB Book Club on 30 January 2024. Two authors will join. Vidya Krishnan, author of The Phantom Plague, and Maria Smilios, author of The Black Angels will discuss their recent books about TB.

The International Union Against Tuberculosis and Lung Disease (The Union) has launched the first issue of IJTLD OPEN – a fully-compliant, open access journal to enhance the coverage of TB and lung disease.

Two out of three adolescents diagnosed with pulmonary tuberculosis (TB) experience lung abnormalities even after successfully completing treatment for this disease.